Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
Looking for a particular Genocea employee's phone or email?
The Genocea annual revenue was $11 million in 2026.
Patricia Manning is the Vice President, Human Resources of Genocea.
3 people are employed at Genocea.
Genocea is based in Cambridge, Massachusetts.
The NAICS codes for Genocea are [325, 3254, 325414, 32541, 32].
The SIC codes for Genocea are [283, 28].